Targeted therapy represents a significant advancement in the medical management of melanoma, providing a more focused approach to treating cancer at a molecular level. Unlike traditional treatments that affect all rapidly dividing cells, targeted medicines are designed to interfere with specific proteins that help cancer cells grow and survive. For many patients in the United Kingdom, these drugs offer an effective way to control the disease by blocking the signals that drive tumour progression.
What We’ll Discuss in This Article
- The clinical definition of targeted therapy for melanoma.
- Identifying the BRAF mutation and its role in cancer growth.
- Eligibility criteria for receiving targeted treatment in the UK.
- The standard drug combinations used in the NHS for BRAF-positive cases.
- How targeted therapy differs from other systemic treatments like immunotherapy.
- The typical duration and administration of targeted medicines.
- Common side effects and how they are managed by clinical teams.
Defining targeted therapy and its biological function
Targeted therapy is a form of systemic treatment that uses drugs to identify and attack specific components of melanoma cells. These medications specifically target the pathways that allow cancer cells to multiply in an uncontrolled manner. In the context of melanoma, the most frequent targets are proteins produced by mutated genes that act as internal switches for cell division. By turning these switches off, the therapy can slow down or even stop the growth of the tumour. Targeted medicines for melanoma are typically recommended for patients with advanced disease or those at high risk of recurrence following surgery.
The role of the BRAF mutation in melanoma
Approximately half of all melanoma cases in the UK involve a specific change in the genetic code known as a BRAF mutation. This mutation causes the BRAF protein to become overactive, sending continuous signals to the cancer cells to grow and divide. Patients whose melanoma contains this genetic change are described as being BRAF-positive. Targeted therapy is particularly effective for this group because the drugs are specifically designed to bind to the mutated BRAF protein and block its activity. Without this mutation, these specific targeted drugs do not have a target to act upon, which is why genetic testing is a mandatory step before treatment begins.
Eligibility and genetic testing for targeted treatment
To determine if a patient is eligible for targeted therapy, a sample of the melanoma tissue must be sent to a specialised laboratory for molecular analysis. This testing is typically performed on patients with Stage 2C, Stage 3, or Stage 4 melanoma. National clinical standards specify that targeted therapy is only suitable for patients whose tumour samples test positive for a specific mutation in the BRAF gene. If the test confirms the presence of the mutation, the patient becomes eligible for several types of targeted medicines. If the melanoma is BRAF-negative, the medical team will instead focus on other treatment options such as immunotherapy, which does not rely on the presence of this specific genetic marker.
Standard drug combinations used in the UK
In modern UK clinical practice, targeted therapy is usually administered as a combination of two different drugs: a BRAF inhibitor and a MEK inhibitor. These two types of drugs work together to block different parts of the same growth pathway, which makes the treatment more effective and reduces the likelihood of the cancer developing resistance. The most common combinations used within the NHS include dabrafenib with trametinib, and encorafenib with binimetinib. Another option sometimes used is the combination of vemurafenib and cobimetinib. These medications are taken as oral tablets or capsules, allowing many patients to manage their treatment from home.
Comparing targeted therapy and immunotherapy
Choosing between targeted therapy and immunotherapy for a BRAF-positive patient is a decision made by the multidisciplinary team based on several clinical factors. Targeted therapy often works very quickly, which can be beneficial for patients who have symptoms from their cancer that need to be managed urgently. Immunotherapy may take longer to show an effect but can sometimes provide a more durable long-term response even after the treatment has stopped. The choice depends on the volume of the disease, the speed at which it is growing, and the individual health profile of the patient. In some cases, a patient may receive one type of treatment first and then switch to the other if the first stops working.
Duration and administration of targeted medicines
The way targeted therapy is used depends on whether it is being given as an adjuvant treatment or for advanced disease. If the drugs are prescribed as adjuvant therapy, which means they are given after surgery to prevent the cancer from returning, they are typically taken for a total of twelve months. For patients with advanced or metastatic melanoma that cannot be removed by surgery, the treatment is usually continued for as long as it remains effective and the side effects are manageable. Regular blood tests and clinical reviews are required throughout the treatment period to monitor the body’s response and ensure the dose is appropriate.
Managing side effects and clinical monitoring
Like all potent medications, targeted therapy can cause a range of side effects as the body reacts to the treatment. Common issues include a high temperature, chills, fatigue, and skin rashes. Some patients may also experience joint pain or changes in their liver function. Because these drugs affect the MEK protein, they can occasionally cause temporary changes in vision or heart function, which are monitored through regular eye checks and heart scans. Most side effects can be managed by adjusting the dose or by taking short breaks from the medication under the guidance of a consultant oncologist. Patients are encouraged to report any new symptoms to their specialist nurse as soon as they occur.
Conclusion
Targeted therapy is a vital treatment option for patients with BRAF-positive melanoma, offering a way to directly interfere with the signals that cause tumours to grow. Eligibility is determined through precise genetic testing of the cancer tissue, and treatment usually involves a combination of oral BRAF and MEK inhibitors. While these drugs can cause various side effects, they provide a focused and effective method for managing high-risk and advanced disease. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
What does BRAF-positive actually mean?
It means the melanoma cells have a specific genetic mutation that produces an overactive protein, which acts as a growth signal for the cancer.
Can I have targeted therapy if I am BRAF-negative?
No, these specific drugs are only effective if the BRAF mutation is present, so other treatments like immunotherapy are used for BRAF-negative cases.
Is targeted therapy a type of chemotherapy?
No, targeted therapy works differently by focusing on specific proteins, whereas chemotherapy is a more general treatment that kills all fast-growing cells.
How do I take the tablets?
Most targeted therapy combinations involve taking tablets once or twice a day, usually at the same time each day to maintain a steady level in your blood.
Can I still work while on targeted therapy?
Many patients are able to continue working, but this depends on how they feel and whether they experience side effects like fatigue or fever.
Will the treatment cure my melanoma?
For some patients, targeted therapy can shrink tumours or keep the cancer stable for a long time, and when used after surgery, it can significantly reduce the risk of recurrence.
What happens if I forget a dose?
You should follow the specific instructions provided by your oncology team, but generally, you should not take a double dose to make up for a forgotten one.
Authority Snapshot (E-E-A-T)
This article is designed to provide clear and factual information regarding skin health for the general public. The content is written by the Medical Content Team and has been reviewed by Dr. Stefan Petrov. He is a UK-trained physician with an MBBS and postgraduate certifications including Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), and the UK Medical Licensing Assessment (PLAB 1 & 2). He has hands-on experience in general medicine, surgery, anaesthesia, ophthalmology, and emergency care. Dr. Petrov has worked in both hospital wards and intensive care units, performing diagnostic and therapeutic procedures, and has contributed to medical education by creating patient-focused health content and teaching clinical skills to junior doctors.
